Orexo strengthens its sustainability work by establishing a social financing framework
07.08.2025 - 18:08:33 | prnewswire.co.ukAbout Orexo
Orexo is a Swedish pharmaceutical company with over 25 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs. On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2023 amounted to SEK 639 million, and the number of employees to 116. Orexo is listed on Nasdaq Stockholm's main list and is available as an ADR on OTCQX (ORXOY) in the US.
For more information about Orexo please visit www.orexo.com. You can also follow Orexo on X, LinkedIn, and YouTube.
Morningstar Sustainalytics, a globally-recognized provider of ESG research, ratings and data, evaluated Orexo's Framework and the alignment thereof with relevant industry standards and provided views on the robustness and credibility of the Framework. In no event shall the Social Financing Framework nor any portion thereof be construed as part of the offering, nor shall be considered as an offer or advertisement to buy a security, solicitation of votes or proxies, investment advice, expert opinion or negative assurance letter as defined by the applicable legislation.
The information was sent for publication, through the agency of the contact person set out above, on March 8, 2024, at 8 CET.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
https://mb.cision.com/Main/694/3942836/2656265.pdf
Orexo_PR_Orexo strengthens its sustainability work by establishing a social financing framework _Publ_March 8 2024
View original content:https://www.prnewswire.co.uk/news-releases/orexo-strengthens-its-sustainability-work-by-establishing-a-social-financing-framework-302083869.html
Hol dir jetzt den Wissensvorsprung der Aktien-Profis.
Für. Immer. Kostenlos.

